Skip to main content

tisagenlecleucel

Generic: tisagenlecleucel·Brand: Kymriah

tisagenlecleucel: 7 clinical trials tracked.

tisagenlecleucel evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about tisagenlecleucel, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 1 study sponsors
Clinical Trials (7)

Managed Access Programs for CTL019, Tisagenlecleucel

NCT03601442·NVS
Available
Expanded AccessNovartis Pharmaceuticals

A Phase I Trial of Lymphodepletion Intensification With Low Dose Total Body Irradiation With Dose Expansion for Standard-of-Care Tisagenlecleucel in Patients With Large B-Cell Lymphoma

NCT07676877·Phase 1
Not yet recruiting

Primary endpoint: Dose-limiting toxicities

Interventionalopen18 targetStarted 2026-09Completion 2027-121 site · United StatesNathan Denlinger

A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL)

NCT05888493·Phase 3·NVS
Active, not recruiting

Primary endpoint: Progression-free survival (PFS) determined by blinded independent review committee (BIRC)

InterventionalRandomizedopen109 targetStarted 2023-10Completion 2031-0230 sites · Australia, Austria, Canada, Czechia…Novartis Pharmaceuticals

A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 a Long-acting Human IL-7, Post-Kymriah®, Post-Yescarta®, or Post-Breyanzi® in Subjects With Relapsed/Refractory Large B-cell Lymphoma

NCT05075603·Phase 1
Completed

Primary endpoint: Incidence, Nature, and Severity of Adverse Events, Graded According to NCI CTCAE v5.0, Except for Cytokine Release Syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), Which Were Graded Based on ASTCT Guidelines

Interventionalopen17 enrolledStarted 2021-07Completion 2025-033 sites · United StatesNeoImmuneTech

A Phase IIIb Study of the Safety and Efficacy of Tisagenlecleucel Out of Specification for Commercial Release in Patients Who Are Consistent With the Label Indication

NCT04094311·Phase 3·NVS
Recruiting

Primary endpoint: Percentage of participants with Adverse Events (AEs)

Interventionalopen200 targetStarted 2019-11Completion 2027-0350 sites · Canada, JapanNovartis Pharmaceuticals

A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy

NCT03876769·Phase 2·NVS
Active, not recruiting

Primary endpoint: Disease Free Survival (DFS) rate without censoring for new anticancer therapy, including Stem Cell Transplantation (SCT) while in remission

Interventionalopen121 enrolledStarted 2019-06Completion 2027-1043 sites · Belgium, Canada, Denmark, France…Novartis Pharmaceuticals

A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma

NCT03568461·Phase 2·NVS
Completed

Primary endpoint: Complete Response Rate (CRR) Per Independent Review Committee (IRC) Assessment

Interventionalopen98 enrolledStarted 2018-11Completion 2025-0530 sites · Australia, Austria, Belgium, France…Novartis Pharmaceuticals